Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease.
Phase of Trial: Phase IV
Latest Information Update: 18 Jun 2014
At a glance
- Drugs Galantamine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms CIRCADIAN
- Sponsors Janssen-Cilag
- 13 Aug 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Mar 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 20 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.